EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States

Hiral Anil Shah iD, Ginita Jutlla iD, Oscar Herrera-Restrepo iD, Jonathan Graham iD, Katherine A Hicks iD, Justin Carrico iD, Mei Grace iD, Diana E Clements iD, Cindy Burman iD, Woo-Yun Sohn iD, Elise Kuylen iD, Shahina Begum iD und 1 weitere

PharmacoEconomics · 2025

DOI: 10.1007/s40273-024-01439-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift PharmacoEconomics, 2025. Verfasst von Hiral Anil Shah und 12 weiteren Autor:innen. Beteiligte Einrichtung: GSK, London, UK. hiral.a.shah@gsk.com. Hauptthemen laut MEDLINE: Meningococcal Vaccines, Meningococcal Infections, Public Health. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GlaxoSmithKline Biologicals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Invasive meningococcal disease (IMD) is primarily associated with five Neisseria meningitidis serogroups: A, B, C, W, or Y. In the United States (US), available vaccines protect against serogroups B (MenB), A, C, W, and Y (MenACWY), and A, B, C, W, and Y (MenABCWY). The Advisory Committee on Immunization Practices is re-evaluating the adolescent meningococcal vaccination schedule with varying recommendation formats. This analysis aimed to predict which schedule could avert the most IMD cases and have the most positive public health impact (PHI). METHODS: An epidemiological model compared the 15-year PHI of vaccination schedules using MenB, MenACWY, and/or MenABCWY vaccines versus current US standard of care (SoC). Varying coverage rates reflected routine, shared clinical decision making, and risk-based recommendations. Sensitivity analyses assessed robustness of the results to different inputs/assumptions. RESULTS: The most positive PHI compared with SoC was observed with one dose of MenACWY at 11 years of age and two doses of MenABCWY (6 months apart) at 16 years of age, assuming routine recommendation and coverage reflecting real-world uptake of MenACWY. This strategy resulted in 123 IMD cases averted (MenB: 59, MenACWY: 64), 17 deaths prevented, 574 life-years saved, and 757 quality-adjusted life-years gained versus SoC. Eliminating MenACWY vaccination at 11 years was found to result in an additional IMD burden. CONCLUSION: A routinely recommended two-dose pentavalent vaccine, with doses administered 6 months apart at 16 years of age, alongside the routinely recommended MenACWY vaccine at 11 years of age, would improve the PHI and benefits of IMD vaccination to society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningococcal VaccinesMeningococcal InfectionsPublic HealthHumansUnited StatesAdolescentImmunization ScheduleChildMaleVaccinationCost-Benefit AnalysisAdultNeisseria meningitidisChild, Preschool

Substanzen

Meningococcal Vaccines

Autor:innen und Institutionen

  • GSK, London, UK. hiral.a.shah@gsk.com.
  • Neisseria Portfolio, Value Evidence & Outcomes Team, 90 Great West Road, Brentford, TW8 9GS, UK. hiral.a.shah@gsk.com.
  • GSK, London, UK.
  • GSK, Philadelphia, PA, USA.
  • RTI Health Solutions, Research Triangle Park, NC, USA.
  • GSK, Durham, NC, USA.

ORCID-Profile: Hiral Anil Shah, Ginita Jutlla, Oscar Herrera-Restrepo, Jonathan Graham, Katherine A Hicks, Justin Carrico, Mei Grace, Diana E Clements, Cindy Burman, Woo-Yun Sohn, Elise Kuylen, Shahina Begum, Zeki Kocaata

Förderung

  • GlaxoSmithKline Biologicals

Zitieren

APA

Shah, H. A., Jutlla, G., Herrera-Restrepo, O., Graham, J., Hicks, K. A., Carrico, J., Grace, M., Clements, D. E., Burman, C., Sohn, W. Y., Kuylen, E., Begum, S., & Kocaata, Z. (2025). Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States. PharmacoEconomics. https://doi.org/10.1007/s40273-024-01439-y

Vancouver

Shah HA, Jutlla G, Herrera-Restrepo O, Graham J, Hicks KA, Carrico J, et al. Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States. PharmacoEconomics. 2025. doi:10.1007/s40273-024-01439-y

BibTeX
@article{Shah2025,
  author = {Shah, Hiral Anil and Jutlla, Ginita and Herrera-Restrepo, Oscar and Graham, Jonathan and Hicks, Katherine A and Carrico, Justin and Grace, Mei and Clements, Diana E and Burman, Cindy and Sohn, Woo-Yun and Kuylen, Elise and Begum, Shahina and Kocaata, Zeki},
  title = {Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States},
  journal = {PharmacoEconomics},
  year = {2025},
  doi = {10.1007/s40273-024-01439-y}
}
Kostenlos starten →